Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.

Rapid Overlay of Chemical Structures (ROCS), which can rapidly identify potentially active compounds by shape comparison, is recognized as a powerful virtual screening tool. By ROCS, a class of novel Hsp90 inhibitors was identified. The calculated binding mode of the most potent hit 36 guided us to design and synthesize a series of analogs (57a-57h). Over 100-fold improvement was achieved in the target-based assay. The most potent compound 57h inhibited Hsp90 with IC50 0.10 ± 0.01 μM. It also showed much improved cell potency and ligand efficiency. Our study showed that ROCS is efficient in the identification of novel cores of Hsp90 inhibitors. 57h can be ideal leads for further optimization.

[1]  Gabriela Chiosis,et al.  Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. , 2006, Journal of medicinal chemistry.

[2]  R. Morimoto,et al.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death. , 2000, Journal of the National Cancer Institute.

[3]  D. Picard,et al.  Heat-shock protein 90, a chaperone for folding and regulation , 2002, Cellular and Molecular Life Sciences CMLS.

[4]  D. Proia,et al.  Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy , 2011, Molecular Cancer Therapeutics.

[5]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[6]  A. Melnick,et al.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models , 2009, Proceedings of the National Academy of Sciences.

[7]  O. H. Griffith,et al.  A robotics-based automated assay for inorganic and organic phosphates. , 1999, Analytical biochemistry.

[8]  R. Scannevin,et al.  Heat shock protein 90: inhibitors in clinical trials. , 2010, Journal of medicinal chemistry.

[9]  L. Margaritis,et al.  Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. , 2007, Current medicinal chemistry.

[10]  L. Pearl,et al.  Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.

[11]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[12]  W. Pratt,et al.  Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage , 2010, Experimental biology and medicine.

[13]  L. Neckers.  Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. , 2003, Current medicinal chemistry.

[14]  S. Kasibhatla,et al.  EC144 is a potent inhibitor of the heat shock protein 90. , 2012, Journal of medicinal chemistry.

[15]  Jianwen Liu,et al.  Development of rapid and highly sensitive HSPA1A promoter-driven luciferase reporter system for assessing oxidative stress associated with low-dose photodynamic therapy , 2013, Cell Stress and Chaperones.

[16]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[17]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[18]  Gabriela Chiosis,et al.  Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. , 2006, Journal of medicinal chemistry.

[19]  J. A. Grant,et al.  A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..

[20]  A Lavecchia,et al.  Virtual screening strategies in drug discovery: a critical review. , 2013, Current medicinal chemistry.

[21]  L. Pearl,et al.  High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. , 2004, Analytical biochemistry.

[22]  P. Purushottamachar,et al.  First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. , 2007, Bioorganic & medicinal chemistry.

[23]  Suli Huang,et al.  Development of stable HSPA1A promoter-driven luciferase reporter HepG2 cells for assessing the toxicity of organic pollutants present in air , 2012, Cell Stress and Chaperones.

[24]  Malgorzata N. Drwal,et al.  Combination of ligand- and structure-based methods in virtual screening. , 2013, Drug discovery today. Technologies.

[25]  P. Workman.  Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. , 2004, Cancer letters.

[26]  T. Ishii,et al.  New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells , 2010, Clinical Cancer Research.

[27]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[28]  Gianni Chessari,et al.  Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.

[29]  P. Miller,et al.  erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. , 1995, Journal of medicinal chemistry.

[30]  S. Larson,et al.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.

[31]  Aurélien Grosdidier,et al.  Identification of human IKK-2 inhibitors of natural origin (Part II): in Silico prediction of IKK-2 inhibitors in natural extracts with known anti-inflammatory activity. , 2011, European journal of medicinal chemistry.

[32]  L. Neckers,et al.  Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. , 1992, Cancer research.

[33]  Yves L Janin,et al.  ATPase inhibitors of heat-shock protein 90, second season. , 2010, Drug discovery today.

[34]  Q. You,et al.  Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening , 2013, PloS one.

[35]  R. Dobrowsky,et al.  Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. , 2012, Journal of medicinal chemistry.

[36]  Gianni Chessari,et al.  Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. , 2010, Journal of medicinal chemistry.

[37]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[38]  P. Workman,et al.  HSP90 as a new therapeutic target for cancer therapy: the story unfolds , 2002, Expert opinion on biological therapy.

[39]  T. Langer,et al.  Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors. , 2010, Bioorganic & medicinal chemistry.

[40]  James R. Porter,et al.  Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.

[41]  J. Koenderink.  Q… , 2014, Les noms officiels des communes de Wallonie, de Bruxelles-Capitale et de la communaute germanophone.

[42]  A. Kamal,et al.  Therapeutic and diagnostic implications of Hsp90 activation , 2004, Trends in Molecular Medicine.

[43]  Y. Naomoto,et al.  HSP90 and its inhibitors. , 2010, Oncology reports.

[44]  F. Spaltmann,et al.  High-throughput assay for inorganic pyrophosphatases using the cytosolic enzymes of Saccharomyces cerevisiae and human as an example. , 2000, Protein expression and purification.

[45]  A. Iafrate,et al.  Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  K. Morano,et al.  Small molecule activators of the heat shock response: chemical properties, molecular targets, and therapeutic promise. , 2012, Chemical research in toxicology.

[47]  Xiong Cai,et al.  CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy , 2009, Clinical Cancer Research.

[48]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[49]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[50]  A. T. Lau,et al.  Post-translational modification of human heat shock factors and their functions: a recent update by proteomic approach. , 2012, Journal of proteome research.

[51]  Andreas Bender,et al.  Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..

[52]  J. Peyrat,et al.  Recent advances in Hsp90 inhibitors as antitumor agents. , 2008, Anti-cancer agents in medicinal chemistry.

[53]  J. Holzbeierlein,et al.  Hsp90: A Drug Target? , 2010, Current oncology reports.